Revolutionizing Minimally Invasive Surgery for Gallbladder Cancer and Enhancing Recovery and Survival Rates: Dr. Vipulroy Rathore ...
Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers with FGFR2 gene fusion mutations ...